BRITISH PHARMACOLOGICAL SOCIETY

Renata Scalco

Renata is a PhD neurologist with a strong focus on clinical development with international experience in neuromuscular disorders, neuropathology (muscle) and neurogenetics working at Roche.
Industry experience: risdiplam (Evrysdi) for SMA - late clinical development / supporting filling activities / approval by different health authorities worldwide.

Renata is a clinician and a scientist with a PhD in Translational Research in Neurology gained at the Queen Square Institute of Neurology, University College London (UCL).

Lutz Mueller

Lutz is a Non-Clinical Project Leader and Chair of the Translational Safety Committee at Roche. Lutz has experience of many years of creating and regulating medicines with the German Health Authority (BfArM), Novartis and Roche.

Lately, Lutz considers his chance to contribute to making the first small molecule mRNA splice modifier into an approved lifesaving drug a key achievement for a drug discoverer. He is proud to have been part of a team in the discovery and launch of Evrysdi (with risdiplam as its active ingredient). Evrysdi helps patients with SMA to survive and to live a life full of hopes such as any other human being on this earth.

Lesley Narburgh

Lesley is Pharma Development Regulatory and Global Franchise Head of Rare Diseases and Neurodegeneration at Roche.

Lesley has over 20 years' experience in the pharmaceutical industry; accountable for global regulatory management of complex project(s), leading and line management for a global team of senior regulatory professionals; passion for rare disease and neurodegeneration drug development looking for innovative, patient centric regulatory solutions.

David Jones

David is a consultant Pharmaco-Toxicologist. David has a career spanning over 25 years at the UK Medicines and Healthcare products Regulatory Agency (MHRA). David is a European Registered Toxicologist and a Fellow of the British Toxicology Society as well as a Chartered Biologist and a Fellow of the Royal Society of Biology. He also lectures at the University of Surrey and the University of Wales. His many years of experience at the MHRA provide invaluable insight to clients looking to take drugs into clinical trials.

BRITISH PHARMACOLOGICAL SOCIETY

Helen Tomkinson

Helen is Managing Director at Limina. A consultancy for Clinical Pharmacology and Bioanalysis.

Helen is a highly motivated leader with a track record of setting strategy, building, and motivating teams in the Clinical Pharmacology, Modelling and simulation and Bioanalytical fields. Helen has experience from Astra Zeneca and specialised in oncology and anti-infectives. More recently Helen has developed broad cross therapy area expertise.

Aaron Deveney

Aaron is Vice President Clinical Development at Weatherden.

Aaron is a senior specialist who has brought to market several compounds and brings extensive experience in the management of development programs, strategic alliances, coordinating global business initiatives and portfolio management.

Kirsty Wydenbach

Kirsty is Head of Regulatory Strategy and Drug Development Clinician at Weatherden.

Kirsty has extensive experience as an expert medical assessor of regulation in clinical trials and more than a decade's experience at the UK Medicines and Healthcare products Regulatory Agency (MHRA).